|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's range||82.19 - 84.70|
|52-week range||65.00 - 94.34|
|PE ratio (TTM)||N/A|
|Earnings date||6 Aug 2018 - 10 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||93.70|
Like millions of people caught up in America’s opioid crisis, Rick Surkin used to take a pill just to get out of bed in the morning. Until last year, the former firefighter relied on thrice-daily doses of the powerful painkiller OxyContin to numb the agony from a ruptured disc in his back. The series of tiny shocks, known as neuromodulation, has kept Surkin comfortable enough to ditch Oxy.
REDWOOD CITY, Calif. (AP) _ Nevro Corp. (NVRO) on Monday reported a loss of $17.7 million in its first quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of 59 cents. The results missed Wall Street expectations.
Spinal cord stimulation isn't as scary as it sounds. Innovation in the devices and a push away from treating chronic pain with opioids are causing the market to boom.
The Redwood City, California-based company said it had a loss of 21 cents per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...